Altamira Therapeutics Ltd. (CYTO)
| Market Cap | 4.93M |
| Revenue (ttm) | -902,126 |
| Net Income (ttm) | -27.38M |
| Shares Out | 1.42M |
| EPS (ttm) | -498.74 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,258,882 |
| Open | 3.19 |
| Previous Close | 3.24 |
| Day's Range | 2.91 - 3.53 |
| 52-Week Range | 1.88 - 119.40 |
| Beta | 2.48 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Sep 12, 2023 |
About CYTO
Altamira Therapeutics Ltd., a clinical-and commercial-stage biopharmaceutical company, engages in the development of therapeutics that address various unmet medical needs in Switzerland, the United States, Europe, and Australia. The company develops OligoPhore/SemaPhore, a platform for delivery of oligonucleotides, such as small interfering ribonucleic acid or messenger RNA into target cells. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also devel... [Read more]
Financial Performance
In 2022, CYTO's revenue was 305,616, an increase of 378.41% compared to the previous year's 63,882. Losses were -26.53 million, 55.5% more than in 2021.
Financial numbers in CHF Financial StatementsNews
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
HAMILTON, BERMUDA, Dec. 29, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA, Dec. 29, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company providing nanoparticle-based...
Altamira Therapeutics to Host Investor & Business Update Call on December 11th
HAMILTON, BERMUDA , Dec. 05, 2023 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA--December 5, 2023--Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing th...
These advisers say markets are expecting unrealistic outcomes. Here are some alternatives.
Stocks are poised for an upbeat finish to the best month of gains for 2023, as the fever pitch around Fed rate cuts next year grows. It's all teeing up nicely for that Santa rally, maybe.
Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement
- Partial spin-off of Bentrio® completed to increase focus on RNA delivery activities - Retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue HAMILTON, BERMUDA, Nov. 29, 2023 ...
Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business
Initiates Strategic Repositioning to Focus on Company's Core RNA Delivery Technology Altamira Therapeutics retains 49% in Altamira Medica AG, and secures 25% of future licensing revenue Hamilton, Berm...
Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine
Hamilton, Bermuda, Nov. 10, 2023 (GLOBE NEWSWIRE) -- November 10, 2023 -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that ad...
Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
HAMILTON, BERMUDA , Sept. 14, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announ...
Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results
HAMILTON, BERMUDA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (NASDAQ:CYTO) ("Altamira" or the "Company"), a company dedicated to addressing unmet medical needs, today provided a bu...
Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th
HAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important un...
Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13
HAMILTON, BERMUDA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unme...
Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia
HAMILTON, BERMUDA, July 20, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unme...
Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal
HAMILTON, BERMUDA, July 17, 2023 (GLOBE NEWSWIRE) -- -Detailed results from house dust mite trial published in Clinical and Translational Allergy -Study demonstrates statistically significant alleviat...
Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering
HAMILTON, BERMUDA / ACCESSWIRE / July 6, 2023 / Altamira Therapeutics Ltd. ("Company") (Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond t...
Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration
HAMILTON, BERMUDA , July 05, 2023 (GLOBE NEWSWIRE) -- Heqet will test nanoparticles based on Altamira's OligoPhore delivery platform in the regeneration of damaged heart tissue
Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome
HAMILTON, BERMUDA / ACCESSWIRE / June 15, 2023 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet med...
Altamira Therapeutics Announces Publication of Peer-Reviewed Article on Peptide-Based RNA Delivery for Extrahepatic Targets
HAMILTON, BERMUDA / ACCESSWIRE / May 31, 2023 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, today announced the...
Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis
Bentrio® meets primary efficacy endpoint in NASAR clinical trial in seasonal allergic rhinitis Clinically relevant and statistically significant improvement in Total Nasal Symptom Score over saline na...
Altamira Therapeutics Provides Business Update, Reports FY 2022 Financial Results
Management will host an investor conference call today, May 16th, at 8 a.m. Eastern Company is advancing OligoPhore™ / SemaPhore™ platform for extrahepatic RNA delivery and efficient endosomal release...
Altamira Therapeutics to Host Fiscal Year 2022 Financial Results and Business Update Call on May 16th 2023
HAMILTON, BERMUDA / ACCESSWIRE / May 12, 2023 / Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing and commercializing RNA delivery technology for extrahepatic targets, announ...
Altamira Therapeutics CEO & Chairman to Present at Sidoti Micro-Cap Virtual Conference May 10-11
HAMILTON, BERMUDA / ACCESSWIRE / May 1, 2023 / Altamira Therapeutics ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing therapeutics that address important unmet medical ne...
Altamira Therapeutics Announces Publication of Positive Results from Phase 2 Trial with AM-125 in Acute Vestibular Syndrome in Leading Peer Reviewed Journal
Detailed results from TRAVERS trial addressing acute vestibular syndrome with AM-125 (intranasal betahistine) published in Otology & Neurotology Study demonstrates proof of concept and shows good tole...
Altamira Therapeutics Positions its Patented SemaPhore mRNA Delivery Platform as Versatile and Efficient Alternative to Lipid Nanoparticles
Altamira's peptide-based SemaPhore™ nanoparticle technology confers great stability to mRNA, is non-immunogenic and non-toxic, enabling delivery to extrahepatic targets and efficient endosomal release...
Altamira Therapeutics Reports Positive Conclusions from Independent Meta-Analysis of Clinical Studies with Betahistine in Treatment of Most Common Cause of Vertigo
Published meta-analysis shows statistically significant improvement in dizziness handicap for betahistine treatment over standard of care procedure alone in patients suffering from BPPV Altamira to fi...
Altamira Therapeutics' SemaPhore Delivery Platform Shows Significant Synergis-tic Effects of ZBTB46 mRNA with PD1 Immunotherapy in Control of Tumor Growth in Animal Model
HAMILTON, BERMUDA, March 22, 2023 (GLOBE NEWSWIRE) -- Altamira Therapeutics ("Altamira" or the "Company") (Nasdaq:CYTO), a company dedicated to developing RNA-based therapeutics that address important...
Altamira Therapeutics' SemaPhore RNA Delivery Platform Drives Effective Treatment of Osteoarthritis with mRNA in Animal Model
Data to be presented at Osteoarthritis Research Society International World Congress in Denver March 17-20, 2023 Animal study shows effective attenuation of osteoarthritis progression and functional i...